Company Overview

Industry Sector: Medical Devices

Company Overview: Sharklet Technologies, Inc. has developed a revolutionary antibacterial surface technology. Aimed squarely at the challenges with microbial contamination, the Sharklet micro-pattern is applied to a variety of products, surfaces, and medical devices to inhibit bacterial colonization and reduce the clinical and economic burden of hospital-acquired infections.

Target Market(s): Major hospitals, medical device manufacturers, and OEMs worldwide.

Management

Leadership:
Joseph W. Bagan, Chairman of the Board
Mark M. Spiecker, Chief Executive Officer
Dr. Anthony Brennan, Chief Technology Officer
Kenneth Chung, Director of Product Development
Dr. Shravanthi Reddy, Director of Research

Scientific Advisory Board:
Anthony Brennan, Ph.D.: Inventor of Sharklet and Endowed Professor in Materials Science and Biomedical Engineering at the University of Florida
Jaime Landman, M.D.: Chair of Urology, UC Irvine
Daniel Perlman, M.D.: President of Infectious Disease Society of America Colorado Chapter
Michael Pietrzak, M.D.: Founder and President of Knowledge Management Solutions

Key Value Drivers

Technology*: Inspired by the microorganism resistant properties of sharkskin, Sharklet™ is a patented surface technology comprised of millions of raised microscopic features arranged in distinct diamond shapes to form a continuous pattern. Each Sharklet diamond measures approximately 26 microns across and nearly three microns in feature height. Laboratory tests show that Sharklet can significantly reduce the attachment and survival of harmful pathogens including MRSA, VRE, and Pseudomonas aeruginosa.

Competitive Advantage: Sharklet™ relies solely on the shape and pattern of the surface alone to disrupt bacterial colonization, not toxic biocides that contribute to drug-resistant ‘superbugs’ such as MRSA. Sharklet is effective against a broad range of bacteria, easily incorporated into most polymer-based medical device, and not reliant upon humans’ adherence to hygiene protocols.

Plan & Strategy: seeking strategic partners to commercialize medical devices and OEM devices.

*Technology funded by the NIDDK and being commercialized under the NIH-CAP

Product Pipeline

Urinary Access Devices
Sharklet Micro-Seal Foley catheter - CE Mark Submission Q1 2013

Airway Management Devices
Sharklet endotracheal tube - Feasibility testing underway, Phase 2 submitted April 5, 2012

Vascular Access Devices
Sharklet central venous catheter